Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemogen (HEMGN)
- Target
- HEMGN
- Molecular classification
- Other (Hemogen is a non-enzymatic, non-receptor regulatory protein; it is a nuclear protein involved in gene regulation but is not categorized under classical druggable target families such as receptors, enzymes, ion channels or transporters)
01
Overview
Hemogen (HEMGN) is a protein that regulates hematopoietic cell proliferation and differentiation, acting as a negative regulator of megakaryocytic differentiation and possibly preventing apoptosis through NF-kB activation[1][6][2]. It is a nuclear protein with predicted involvement in osteoblast differentiation, but it is not classified as a receptor, enzyme, transporter, or transcription factor[1][4]. Hemogen is associated with congenital contractural arachnodactyly and broadly influences processes relevant to blood cell formation and survival, though it is not a current therapeutic target and there are no known drugs that interact directly with it[1][6].
- Other names
- EDAGNDRPRO1037PRO1620EDAG-1CT155erythroid differentiation-associated gene proteinhemopoietic gene proteinnegative differentiation regulator protein
02
Biological functions
Regulation of hematopoietic cell proliferation and differentiationNegative regulation of differentiation (especially megakaryocytic lineage)Prevention of apoptosis via NF-kB activationRegulation of osteoblast differentiation
03
Disease associations
Cancer (by implication of its role in cell proliferation/differentiation, though specific oncogenic associations are not well-established in the cited literature)Congenital contractural arachnodactyly (reported genetic association)Other (as above, general regulation in hematopoiesis may implicate it in hematological disorders)
04
Safety considerations
Dysregulation may affect hematopoiesis or cell differentiation, potentially contributing to disease but not established as a direct safety concern in therapeutic context
Beyond the preview
Go deeper on Hemogen (HEMGN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemogen (HEMGN).